| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Instil Bio, Inc.$7.7
+0.04 (+0.52%)
F 16Pipeline Score Biotech · Pre-Clinical
Market Cap
55.48 M
EPS
-7.08
P/E Ratio
-
Value Trade
120.07 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
669.00 K
Operating CF
-1.34 M
Total Assets
200.43 M
Total Liabilities
89.73 M
Equity
110.70 M
D/E Ratio
12,345
0.49 %
Week
-2.73 %
1 Month
-12.33 %
3 Month
-32.67 %
6 Month
-97.8 %
5 Year
-98.49 %
All Time
Cash Data
Cash Position
74.57 M
Monthly Burn
446.00 K
Runway
165.6 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
10.09 K
52 Week Range
5.67 - 42.79
% held by Insiders
40.4 %
% held by Institutions
26.71 %
Enterprise Value
65.97 M
Total Shares
6.79 M
Short %
5.66 %
Float Shares
4.15 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Instil Bio, Inc.
191Total events
2Upcoming
31Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
Event history 189
Jun 2026
◆Trial InitiationIMM2510Trial
Phase 3 trial of '2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China
first-line NSCLCsource ↗
May 15, 2026
●Runway Guidance UpdateCorporate
Cash position of $74.7M expected to fund operating plan beyond 2027
Mar 27, 2026
▲Runway Guidance UpdateCorporate
Cash position of $76.3M expected to fund operations beyond 2027
Jan 6, 2026
▼Program DiscontinuationAXN-2510DiscontinuedCorporate
Discontinuation of clinical development of AXN-2510
Jan 6, 2026
▼Partnership / LicenseAXN-2510DiscontinuedCorporate
Termination of license and collaboration agreement for AXN-2510 and AXN-27M
Jan 6, 2026
▼Trial DiscontinuedAXN-2510DiscontinuedTrial
Discontinuation of clinical development of AXN-2510
Jan 2026
▼Program DiscontinuationAXN-2510DiscontinuedCorporate
Discontinued clinical development of AXN-2510
Jan 2026
▼Partnership / LicenseAXN-2510DiscontinuedCorporate
Terminated license and collaboration agreement for AXN-2510 and AXN-27M
2025
▲Runway Guidance UpdateCorporate
Cash runway expected into 2025 upon sale-leaseback of Tarzana facility
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 12%
Micro Cap (rank 803 of 911)
Percentile RankInstil Bio, Inc. has significant pipeline risk (16/100).
Showing 0 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
'2510 | squamous non-small cell lung cancer | Phase 1 | 2025-09-10 | In a Phase 1 trial, ‘2510 demonstrated an objective response rate (ORR) of 35.3% in 17 evaluable patients with previously treated squamous non-small cell lung cancer, with the majority of responses occurring in patients with negative and low PD-L1 TPS scores. Read More | Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) Read More | |
'2510 | squamous non-small cell lung cancer | Phase 1 | 2025-09-10 | In a Phase 1 trial, ‘2510 demonstrated an objective response rate (ORR) of 35.3% in 17 evaluable patients with previously treated squamous non-small cell lung cancer, with the majority of responses occurring in patients with negative and low PD-L1 TPS scores. Read More | Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) Read More | |
'2510 | squamous non-small cell lung cancer | Phase 1 | 2025-09-10 | In a Phase 1 trial, ‘2510 demonstrated an objective response rate (ORR) of 35.3% in 17 evaluable patients with previously treated squamous non-small cell lung cancer, with the majority of responses occurring in patients with negative and low PD-L1 TPS scores. Read More | Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TIL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TIL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TILInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported its Q1 2026 financial results, highlighting a cash position of $74.7 million, which is expected to fund operations beyond 2027. The company is exploring acquisitions and in-licensing opportunities to enhance its therapeutic pipeline. While expenses have decreased, the net loss per share remains a concern despite improvements from the previous year.
Read more →TIL▼ -5.5%on this news
Instil Bio, Inc. Investigated by the Portnoy Law Firm
Instil Bio, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, following a drastic drop in stock price. The company's shares plummeted 45.81% after announcing the discontinuation of significant drug development programs and the termination of a collaboration agreement with ImmuneOnco Biopharmaceuticals. This has raised alarms among investors about the financial stability and future prospects of Instil. The firm is promoting the opportunity for affected investors to pursue legal actions to recover losses.
Read more →TIL▼ -6.8%on this news
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a cash position of $76.3 million. The company plans to focus on strategic development through potential acquisitions and in-licensing opportunities. However, it discontinued clinical development of AXN-2510, indicating a shift in its operational strategy. Despite a significant net loss, management remains optimistic about future value creation.
Read more →TIL▼ -45.8%on this news
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Instil Bio's subsidiary, Axion Bio, has halted the clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals. As a result, all global development and commercial rights outside Greater China have reverted to ImmuneOnco. Axion retains a limited license to wind down clinical activities, but the decision signals significant setbacks for Instil Bio's portfolio. The company may also face broader risks related to regulatory processes and macroeconomic factors.
Read more →TIL▼ -7.2%on this news
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its third quarter 2025 financial results, showing a cash position of $83.4 million, which is expected to fund operations beyond 2026. The company experienced a decrease in net loss per share compared to the previous year, while research and development expenses rose significantly. However, restructuring charges increased, and total cash and marketable securities decreased from the prior year.
Read more →TIL▼ -9.8%on this news
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
Instil Bio announced promising preliminary data for its bispecific antibody, '2510', presented by ImmuneOnco at the 2025 World Conference on Lung Cancer. The Phase 1 study showed a 35.3% objective response rate in patients with previously treated squamous non-small cell lung cancer. The treatment was generally well tolerated, although two serious adverse events were noted. Enrollment continues at the highest dose level.
Read more →TILInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its second quarter 2025 financial results, revealing a cash position of $103.6 million, sufficient to support operations beyond 2026. A significant milestone includes the clearance of the Investigational New Drug application for the AXN-2510 therapy, with a clinical trial anticipated before the end of 2025. The company will also present new data at the upcoming IASLC World Conference on Lung Cancer, signaling progress in their clinical programs. However, the company recorded an increase in net losses and faced restructuring charges during this period.
Read more →TIL▼ -11.1%on this news
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
ImmuneOnco Biopharmaceuticals announced preliminary results from a Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy for front-line NSCLC in China. The study showed an 80% partial response rate in squamous patients and 46% in non-squamous patients, with a favorable safety profile. Further data will be presented at a future conference, and the company plans to advance to Phase 3 trials.
Read more →TIL▲ +8.6%on this news· ran to +25% by day 1
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Instil Bio has received FDA clearance for its Investigational New Drug application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF. The company plans to initiate a Phase 1 trial for relapsed/refractory solid tumors before the end of 2025. Initial results from a Phase 2 trial in combination with chemotherapy are anticipated in the second half of 2025.
Read more →TILInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Instil Bio has appointed Dr. John Maraganore to its Board of Directors to enhance the development of AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, particularly non-small cell lung cancer. Dr. Maraganore's extensive experience in biotechnology is expected to guide the program's advancement as it approaches the completion of its Phase 2 trial. His strategic insights are viewed as critical for maximizing the program's value.
Read more →TIL▲ +10%on this news
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Instil Bio has appointed Dr. Jamie Freedman as Chief Medical Officer, bringing over 20 years of experience in oncology drug development. Dr. Freedman aims to advance the development of AXN-2510, a promising bispecific antibody targeting solid tumors. His extensive background includes leadership roles at major pharmaceutical companies and a commitment to health equity.
Read more →TIL▼ -11.2%on this newsshared move
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Instil Bio, a clinical-stage biopharmaceutical company, announced its participation in the 2025 Jefferies Global Healthcare Conference. CEO Bronson Crouch will present on June 5, 2025, at 4:20 PM ET. The company is known for its lead asset, AXN-2510, a bispecific antibody targeting multiple solid tumors. A live webcast of the presentation will be available.
Read more →TIL▼ -14.6%on this news
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio and ImmuneOnco will host an investor and analyst breakfast on May 31, 2025, in Chicago. The event aims to discuss the evolving landscape of PD-(L)1xVEGF bispecific antibodies and share recent clinical trial updates. Attendees are encouraged to register in advance to secure their seats.
Read more →TIL▲ +51.7%on this news· ran to +65% by day 3shared move
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Instil Bio and ImmuneOnco have announced that the Phase 2 trial of IMM2510 in combination with chemotherapy for first-line NSCLC is on track for enrollment completion by Q3 2025, with initial results expected in the second half of 2025. The companies are also preparing for a Phase 3 trial anticipated to start in mid-2026, pending regulatory discussions. The collaboration aims to leverage the bispecific antibody's potential in treating multiple solid tumors.
Read more →TIL▼ -6.9%on this news
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio reported its first-quarter financial results for 2025, highlighting ongoing enrollment in clinical trials for its lead asset AXN-2510 in first-line non-small cell lung cancer (NSCLC). The company has significant cash reserves that will fund operations into 2026 and is preparing to initiate a U.S. clinical study for the asset by the end of 2025, contingent on regulatory approvals. However, the company experienced a substantial rise in restructuring charges and an increase in net loss per share compared to the same period last year, which may prompt scrutiny from investors.
Read more →TILInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Instil Bio has reported its fourth quarter and full year 2024 financial results, revealing a significant cash position of $115.1 million. The company anticipates clinical data updates for its drug AXN-2510/IMM2510 in relapsed/refractory NSCLC in the first half of 2025 and plans to begin enrolling patients for a trial in China in Q2 2025. A U.S. study is also expected to start before the end of 2025, contingent on regulatory approval. Despite positive developments, the company continues to face financial losses and regulatory uncertainties.
Read more →TIL▲ +5.3%on this news
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio announced progress regarding its IMM2510/SYN-2510 bispecific antibody in collaboration with ImmuneOnco in China. The Phase 1b/2 trial has commenced, with the first patient enrolled in a study targeting advanced non-small cell lung cancer (NSCLC) combined with chemotherapy. Initial clinical data from this trial is projected to be available in the second half of 2025, which may influence further global studies. Simultaneously, Instil expects to initiate its own U.S. trial for the same indication, pending regulatory approvals.
Read more →TIL▼ -5.5%on this news· ran to -25% by day 3
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio reported its third quarter 2024 financial results, revealing a strategic licensing agreement for SYN-2510, a PD-L1xVEGF bispecific antibody. The company anticipates clinical updates in 2025 and is initiating multiple studies for SYN-2510 in both China and the U.S. Financially, Instil holds $122.9 million in cash and securities, expected to support operations past 2026. Despite positive developments, the company continues to face significant net losses.
Read more →TIL▼ -23.9%on this news
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Instil Bio and ImmuneOnco have announced a global registrational strategy for their PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Phase 1b/2 trials in China are set to begin in late 2024 for NSCLC and early 2025 for TNBC. An IND submission for SYN-2510 in the US is planned for late 2024, focusing on a Phase 2 trial in second-line NSCLC. The companies aim to address significant unmet medical needs in these cancers with their innovative treatment approach.
Read more →TILInstil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its second quarter 2024 financial results, showcasing the in-licensing of two promising therapeutics, SYN-2510 and SYN-27M, aimed at enhancing its pipeline of novel therapies. The company also entered a 15-year lease agreement for its cell therapy manufacturing facility with AstraZeneca Pharmaceuticals, improving its financial stability. However, Instil reported significant net losses year-over-year and acknowledged ongoing uncertainties regarding clinical trial outcomes and regulatory pathways. The firm anticipates a cash runway that extends beyond 2026 to support its development plans.
Read more →TILInstil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
Instil Bio, Inc. has entered a collaboration agreement with ImmuneOnco Biopharmaceuticals for the development of two promising immunotherapeutic agents, IMM2510 and IMM27M. Under this agreement, Instil gains global development rights outside of Greater China, while ImmuneOnco maintains rights in that region. Both drug candidates are showing encouraging results in clinical trials, targeting advanced solid tumors. The agreement includes substantial potential financial incentives for Instil, significantly bolstering its development pipeline.
Read more →TILInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio reported its first quarter 2024 financial results, showing a cash position that is expected to sustain operations beyond 2026. The company completed feasibility studies aimed at initiating trials for non-small cell lung cancer therapies. Notably, research and development expenses significantly decreased compared to the previous year, while the net loss per share improved. Overall, Instil is also exploring opportunities to in-license and acquire new therapeutic candidates.
Read more →TILInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its financial results for the fourth quarter and full year of 2023, highlighting a strategic collaboration for a potential trial in non-small cell lung cancer in China. However, the company announced the closure of its UK manufacturing and the cessation of the ITIL-306 clinical trial. Despite a sizeable reduction in operating expenses, restructuring charges remained elevated, leading to a persistent net loss. The company expects to have sufficient funds for operations well into 2026.
Read more →TILInstil Bio Announces Strategic Update
Instil Bio, Inc. has announced a strategic update, entering into an agreement with a collaborator to conduct preclinical manufacturing feasibility studies for its ITIL-306 program. If successful, this may lead to an investigator-initiated clinical trial for non-small cell lung cancer in China. In conjunction with this, the company plans to close its UK manufacturing and clinical operations and reduce its workforce. Despite this restructuring, Instil aims to retain key personnel for the advancement of its early-stage pipeline and focuses on developing its CoStAR™ platform.
Read more →TILInstil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
Instil Bio, Inc. (NASDAQ: TIL) announced a 1-for-20 reverse stock split effective December 7, 2023, to regain compliance with Nasdaq's minimum bid price requirements. Starting December 8, shares will trade on a split-adjusted basis, reducing the number of outstanding shares from approximately 130.1 million to about 6.5 million. The company remains focused on developing tumor infiltrating lymphocyte therapies while retaining its NASDAQ ticker symbol 'TIL'.
Read more →TILInstil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio, Inc. released its financial results for the third quarter of 2023, revealing a notable decrease in cash and significant restructuring charges. Despite facing financial losses, the company highlighted positive advancements in its therapeutic technologies, particularly through CoStAR, which reportedly enhances T cell activity. The firm anticipates that its financial resources will sustain operations beyond 2026 and plans to present initial data from a Phase 1 clinical trial in 2024. Overall, while there are challenges, the company is making progress in its clinical and operational objectives.
Read more →TILInstil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Instil Bio, Inc. announced two poster presentations at the SITC 2023 Annual Meeting highlighting significant preclinical data related to its CoStimulatory Antigen Receptor (CoStAR) platform. The data indicates that CoStAR enhances the activity of CD4+ T cells, which may expand tumor-killing capabilities beyond traditional CD8+ T cells. Findings include improved cytokine secretion and cytotoxic function among CD4+ T cells, potentially indicating broader therapeutic implications for TIL therapies.
Read more →TIL▼ -5.2%on this news
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its second quarter 2023 financial results and provided updates on its clinical development. The company anticipates starting the ITIL-306-202 clinical trial in the second half of 2023, with initial data expected in 2024. Manufacturing improvements in their UK facility have resulted in a doubling of the final yield of CoStAR-TILs. Despite a cash runway projected beyond 2026, the company continues to face significant operating losses and incurred substantial restructuring charges.
Read more →TILInstil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Instil Bio has presented encouraging preclinical data at the British Society for Gene and Cell Therapy Annual Conference, showcasing the efficacy of its CoStimulatory Antigen Receptor (CoStAR) platform. The findings indicate that this technology significantly boosts the effectiveness of tumor infiltrating lymphocytes (TILs) against various solid tumors, including non-small cell lung cancer, ovarian, and renal tumors. Instil plans to resume clinical studies for its next-generation TIL therapy, ITIL-306, with initial clinical data expected in 2024.
Read more →TIL▼ -7.4%on this news
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Instil Bio has reported its first quarter financial results for 2023, highlighting the anticipated initiation of its ITIL-306 phase 1 clinical study in the second half of 2023 pending clearance from the MHRA. The company has confirmed a cash runway extending beyond 2026, which supports ongoing operations and research activities. However, it also reported significant restructuring costs and an increased net loss compared to the same period last year, reflecting some financial challenges. The initial clinical data from the new phase 1 study is expected in 2024, which may prove critical for future developments.
Read more →TILInstil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its fourth quarter and full-year financial results for 2022, confirming a cash runway extending beyond 2026 following the consolidation of operations to the UK. The company anticipates initiating its phase 1 study of ITIL-306 in the second half of 2023, with initial clinical data expected in 2024. However, it faced challenges including the discontinuation of the ITIL-168 program due to manufacturing issues and reported restructuring charges.
Read more →TILInstil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Instil Bio, Inc. has announced an extension of its cash runway beyond 2026, thanks to the consolidation of its research and development operations in Manchester, U.K. The company expects initial clinical data from its ITIL-306 program to be available later in 2023. This move follows a reduction-in-force affecting approximately 15 employees in the U.S. to enhance global business operations. Instil aims to leverage its Manchester facility's experience in manufacturing tumor infiltrating lymphocyte therapies as it progresses towards clinical trials.
Read more →TIL▲ +5.7%on this news· ran to +23% by day 3
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Instil Bio has announced the resumption of its Phase 1 clinical trial for ITIL-306, aimed at treating non-small cell lung cancer, ovarian cancer, and renal cell carcinoma. The trial was previously paused but has now reopened due to additional quality safeguards implemented in the manufacturing process. The company anticipates releasing initial safety and efficacy data within 2023. Furthermore, Instil Bio's corporate restructuring is expected to extend their cash runway into 2025, enhancing their position for future clinical developments.
Read more →TIL▼ -6.2%on this news
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Instil Bio, Inc. (“Instil Bio” or the “Company”) (NASDAQ: TIL) on behalf of Instil Bio stockholders. Our investi
Read more →TIL▼ -19.7%on this news· ran to -45% by day 3
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
Discontinuing unmodified TIL programs, including DELTA-1 and DELTA-2 trials of ITIL-168 Prioritizing CoStAR-TIL programs for clinical development, including ITIL-306 in Phase 1 trial for NSCLC, ovarian, and renal cell carcinoma Reducing U.S. headcount by approximately 60% DALL
Read more →TIL▼ -7.7%on this news· ran to -20% by day 3
Document Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168
Read more →TIL▼ -7.7%on this news· ran to -20% by day 3
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1’23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineere
Read more →TILInstil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations o
Read more →TILInstil Bio, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 03, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Instil Bio, Inc. (“Instill Bio”) (NASDAQ: TIL) investors that the law firm has initiated an investigation on beha
Read more →TIL▼ -37.1%on this news· ran to -50% by day 3shared move
Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment should contact the firm to learn more about how they might recover
Read more →TIL▼ -37.1%on this news· ran to -50% by day 3shared move
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
Voluntarily paused enrollment in ITIL-168 and ITIL-306 trials pending outcome of manufacturing analysis and implementation of corrective actions No regulatory agency, including the FDA, has notified the Company of a clinical hold in any of its clinical trials Observed decreased
Read more →TIL▼ -7.1%on this news
Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company manageme
Read more →TILInstil Bio to Present at Morgan Stanley Global Healthcare Conference
DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company manageme
Read more →TILInstil Bio Announces Appointment of Tim Moore as Chief Operating Officer
DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Ti
Read more →TILInstil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H 2023 with top-line clinical data
Read more →TILDocument Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturin
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registr
Read more →TIL▼ -24.3%on this news
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of NSCLC, RCC, and ovarian cancer Instil to present in vivo data with CoStAR T cells demonstrating enhanced expansion, persistence, and tumor control at the 2022 AS
Read more →TIL▼ -5.1%on this news
Instil Bio to Present Novel TIL Analytics at American Society of Gene and Cell Therapy (ASGCT)
DALLAS, May 18, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced results of genomic and
Read more →TIL▲ +8.7%on this newsshared move
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022 Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022 Cash runway into 2024 through key clinical data expected in 2023 DALLAS, May 16, 2022 (GLOBE NEWSWIRE) -- Instil Bio,
Read more →TILInstil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate, ITIL-168, in melanoma - Expansion of manufacturing capacity in Manchester, UK, with
Read more →TILInstil Bio to Present at the Cowen 42nd Annual Health Care Conference
DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will
Read more →TILInstil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations d
Read more →TILInstil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1) Fast Track Designation granted by FDA for ITIL-168 in metastatic melanoma CoStAR mechanism of action data presented at SITC 2021 Successful pre-IND meeting for ITIL-306 DALLAS, Nov. 1
Read more →TILInstil Bio to Present at Upcoming Investor Conferences in November
DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company managemen
Read more →TILInstil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, announced today that a subset analysi
Read more →TILInstil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma Additional Cohorts: ITIL-168 clinical trial expanded during IND review process with two additional cohorts, broadening the study target population DALLAS, Sept. 13, 2021 (GL
Read more →TILInstil Bio to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company manageme
Read more →TILInstil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from the U.S. FDA for lead asset ITIL-168 - Developed 21-day manufacturing process for
Read more →TILInstil Bio to Present at the Jefferies Virtual Healthcare Conference
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will p
Read more →TILInstil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
IPO in March 2021 raising $368M in gross proceeds Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168 DALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company developing tum
Read more →TILInstil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy. “The Orphan Drug Designation
Read more →TILInstil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, April 12, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused
Read more →TILInstil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the closing of its p
Read more →TILInstil Bio Announces Pricing of Upsized Initial Public Offering
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer, today announced the pricing of its u
Read more →Competitive Position
How TIL ranks across every disease it competes inCompetitive Position is a premium feature
See how TIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial